Advertisement

Topics

August 2017 Cysto-Conray II [Iothalamate Meglumine Injection USP 17.2%] Rx only | Cysto-Conray II [Liebel-Flarsheim Company LLC] | BioPortfolio

13:40 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

NOT FOR INTRAVASCULAR ADMINISTRATION

NOT FOR INTRATHECAL USE

Cysto-Conray II is a sterile aqueous solution intended for instillation as a diagnostic radiopaque medium. Cysto-Conray II contains 17.2% w/v iothalamate meglumine which is 1-Deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6-triiodo-N-methylisophthalamate (salt) and has the following structural formula:

Each milliliter of Cysto-Conray II contains 172 mg of iothalamate meglumine, equivalent to 81 mg (8.1% w/v) of organically bound iodine, 0.110 mg edetate calcium disodium as a stabilizer and 0.115 mg of monobasic sodium phosphate as a buffer.

Cysto-Conray II is hypertonic under conditions of use and is supplied in containers from which the air has been displaced by nitrogen. The pH of Cysto-Conray II is 6.6 to 7.6.

The most important characteristic of contrast media is the iodine content.  The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast.

Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the lower urinary tract. Clinical literature reports indicate that routinely less than 1 percent of a retrograde urographic radiopaque is absorbed systemically, however, as much as 12 percent absorption was observed with pyelorenal back flow and may produce iodine medicated thyrotropic effects described under PRECAUTIONS .

Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.

See WARNINGS concerning inadvertant intrathecal administration.

SEVERE ADVERSE EVENTS – INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this drug product is not administered intrathecally.

Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. After administration of the radiocontrast agent, competent personnel and emergency facilities should be available for at least 30 to 60 minutes since delayed reactions have occurred (see ADVERSE REACTIONS ).

The possibility of an idiosyncratic reaction in susceptible patients should always be considered (see ADVERSE REACTIONS ). The susceptible population includes patients with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se and patients with a known clinical hypersensitivity: bronchial asthma, hay fever and food allergies.

A positive history of allergies or hypersensitivity does not arbitrarily contraindicate the use of a contrast agent where a diagnostic procedure is thought essential, but caution should be exercised (see ADVERSE REACTIONS ). Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions in such patients should be considered. Recent reports indicate that such pre-treatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.

Since these procedures require instrumentation, special precautions should be observed in those patients known to have an acute urinary tract infection.

Filling of the bladder should be done at a steady rate, exercising caution to avoid excessive pressure. Sterile procedures should be employed in administration.

No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential or whether this drug affects fertility in males or females.

Category C. Animal reproduction studies have not been conducted with Cysto-Conray II. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cysto-Conray II should be used in pregnant women only if clearly needed.

Iothalamate salts are excreted unchanged in human milk. Although it has not been established that serious adverse reactions occur in nursing infants, because of the potential for adverse reactions, caution should be exercised when Cysto-Conray II is administered to a nursing woman.

Patients receiving diagnostic agents for instillation urography should be instructed to:

Thyroid Function Tests – If indicated, these tests generally should be performed prior to the administration of any iodinated agent. However, thyroid function can be evaluated after use of these agents by using T resin uptake or free thyroxine assays.

Irritation of the bladder or ureter, common to some degree to all contrast media administered for retrograde urographic procedures, may occasionally occur.

As with all contrast media, intravasation may lead to hypersensitivity reactions such as a sense of warmth, flushing, sneezing, sweating, chills, fever, urticaria, laryngeal edema, bronchospasm, hypertension, hypotension, cardiac arrhythmias and cardiac arrest.

Adverse reactions associated with procedural technique include injury to the urethra, bladder, ureter, and introduction of infection.

In the event of serious or anaphylactoid reactions, it should be kept in mind that the reactions known to occur with intravenous administration of radiopaque contrast materials are possible.

Unless contraindicated, an appropriate laxative is given the night before the examination.

The radiographic procedure normally employed for cystography and cystourethrography should be employed. A preliminary radiograph is recommended before the contrast agent is administered.

Sterile catherization is essential. Cysto-Conray II may be introduced by gravity flow using an appropriate venoclysis set or by syringe. Excessive pressure should be avoided with any method of administration.

Cystography and Cystourethrography – Either Conray 43 supplied at 43% w/v or Cysto-Conray II supplied at a 17.2% w/v concentration may be used for these procedures. The desired concentration will vary depending upon the patient’s size and age and also with the technique and equipment used. (SEE CONRAY 43 PACKAGE INSERT FOR SPECIFIC INFORMATION ABOUT THE USE OF THIS PRODUCT.) Sufficient volume of contrast medium is administered to adequately fill the urinary bladder. The volume of solution required will vary depending upon the individual patient. Adults usually require a volume in the range of 200 to 400 mL. Children require a volume in proportion to their body size. The usual dose ranges from 30 to 300 mL.

Cysto-Conray® II Glass Bottles NDC Number
 12 x 250 mL single dose bottles  0019-0862-50

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Exposing this product to very cold temperatures may result in crystallization of the salt. If this occurs, the containers should be brought to room temperature. Shake vigorously to assure complete dissolution of any crystals. The speed of dissolution may be increased by heating with circulating warm air. Before use, examine the product to assure that all solids are redissolved and that the container and closure have not been damaged.

This product is sensitive to light and must be protected from strong daylight or direct exposure to the sun.

As with all contrast media, the containers should be inspected prior to use to ensure that breakage or other damage has not occurred during shipping and handling. All containers should be inspected for closure integrity. Damaged containers should not be used.

Manufactured by: Liebel-Flarsheim Company LLCRaleigh, NC 27616 

Made in USA

GBT 0862A0817Revised 08/17     

Guerbet

Not For Intravascular AdministrationSterile Solution

Cysto-Conray ll 250 mL NDC 0019-0862-50

Iothalamate Meglumine Injection USP 17.2% 81 mg/mL Organically Bound IodineFor Retrograde Cystography and Cystourethrography

NOT FOR INTRATHECAL USERx Only

Protect from light • Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  Each mL contains 172 mg iothalamate meglumine, 0.110 mg edetate calcium disodium as a stabilizer, and 0.115 mg monobasic sodium phosphate as a buffer. Single dose container • Discard unused portionUsual Dosage: See Package Insert.

10230817

Guerbet

Manufactured by:Liebel-Flarsheim Company LLCRaleigh, NC 27616

Made in USA

Manufacturer

Liebel-Flarsheim Company LLC

Active Ingredients

Source

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Conray 43 [liebel-flarsheim company llc]

August 2017Conray 43[Iothalamate Meglumine Injection USP 43%]Rx only

Hypaque-cysto™(diatrizoate meglumine injection, usp)30% [amersham health inc.]

HYPAQUE-CYSTO™(Diatrizoate Meglumine Injection, USP)30%

Conray [liebel-flarsheim company llc]

August 2017 Conray (Iothalamate Meglumine Injection USP 60%)

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Radiological Re-evaluation of Failed Anastomotic Uretheroplasty for PFUDDI Using Computed Tomographic and Magnetic Resonance Urethrography

Estate vlue of CTU and MRU in evaluation of failed anastomotic urethroplasty for pelvic fracture urethral distraction defect injury[PFUDDI] combared to retrograde urethrography and voiding...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

'Candy Sign' in EUS guided cysto-gastrostomy of pancreatic fluid collection with metal stent.

A 40-year-old male underwent EUS guided drainage for symptomatic large WON (15 x 9 cm) due severe acute pancreatitis 6 months ago. The initial steps of EUS guided cysto-gastrostomy with BFMS (needle p...

Clinical and radiological outcomes following surgical treatment for intra-cranial arachnoid cysts.

Intra-cranial arachnoid cysts are benign lesions which are usually incidental, however can produce neurological symptoms due to mass effect as they enlarge. Controversy still exists regarding the opti...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record